---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-068190"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-07-28T23:59:59+00:00"
generated_at: "2026-05-18T00:19:35.766271+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed to present INM-901 preclinical data at AAIC 2025; long-term study shows multi-modal activity

## Summary
- Preclinical data from INM-901 program presented at Alzheimer's Association International Conference (AAIC) 2025 in Toronto.
- Long-term study in 5xFAD mouse model with advanced disease; treatment duration longer than previous studies.
- INM-901 reduced inflammatory biomarkers IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, NfL in dose-dependent manner.
- Immunohistochemistry showed dose-dependent reduction in amyloid-beta immunoreactivity and partial restoration of MAP2.
- Behavioral improvements: cognitive function, anxiety-related behavior, sensory responsiveness restored or approaching normal.

## SEC filing metadata
- accession: 0001213900-25-068190
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025068190/0001213900-25-068190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025068190/ea0250489-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-068190
- JSON: https://secwatch.observer/filing/0001213900-25-068190.json
- Plain text: https://secwatch.observer/filing/0001213900-25-068190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.